Healthcare Industry News: diabetes
News Release - February 2, 2016
Lupin Launches Generic Glumetza(R) HCI ER Tablets in the USMUMBAI and BALTIMORE, February 2, 2016 -- (Healthcare Sales & Marketing Network) -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc., has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s GlumetzaŽ HCl ER Tablets, 500 mg and 1000 mg.
Lupin's Metformin HCl ER Tablets, 500 mg and 1000 mg are the AB-rated generic equivalent of Santarus Inc.'s GlumetzaŽ HCl ER Tablets, 500 mg and 1000 mg strengths. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.
Lupin is eligible for 180 days of generic drug exclusivity for its Metformin HCl ER Tablets, 500 mg and 1000 mg. GlumetzaŽ HCI ER Tablets had US sales of USD 450.4 million (IMS MAT September 2015).
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space, and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th - IMS Health). For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively.
About Lupin Pharmaceuticals Inc. (LPI):
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.
Please visit http://www.lupin.com for more information.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.